Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (1294)	9/28/1998 12:55:00 PM
From: crysball	Read Replies (1) \| Respond to of 1491

No FDA approval required for US Army. The intriguing aspect of the WSJ article is the ongoing testing at the US Army. The problem is......no ethical way to conduct a clinical trial forHU-211 on human nerve gas victims. If the Army can develop a test protocol they consider adequate to evaluate efficacy they can contract directly with PARS....no FDA approval required. Animal models are probably inadequate to base a decision of magnitude (purchasing and stockpiling millions of doses) upon. If the US Army would start to stockpile HU-211 (assuming it has no shelf life issues), other at risk nations would likely follow. Although the WSJ article hints at some financial arrangement for the the U.S Army purchase of HU-211, wouldn't you expect PARS to have reported this? Also a different delivery system would probably be required for nerve gas indications, since battlefield conditions don't lend themselves to I-V drips for combatants.